Cabaletta Bio officer buys 11,312 shares at $2.1891

Cabaletta Bio, Inc. officer Gwendolyn Binder, President, Science & Tech., reported an open-market purchase of company stock.

Accepted by SEC EDGAR 01/21/2026 - 06:56 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Cabaletta Bio, Inc. officer Gwendolyn Binder, President, Science & Tech., reported an open-market purchase of company stock. On January 21, 2026, she bought 11,312 shares of Cabaletta Bio common stock at a price of $2.1891 per share.

Following this transaction, Binder directly holds a total of 31,312 shares of Cabaletta Bio common stock, according to the filing.

Insider Trade Summary

Net Buyer: 11,312 shares

Net Buy 1 txn

Insider Binder Gwendolyn

Role President, Science & Tech.

Bought 11,312 shs ($25K)

Increase in Position 56.6%

Type	Security	Shares	Price	Value
Purchase	Common Stock	11,312	$2.1891	$25K

Holdings After Transaction: Common Stock — 31,312 shares (Direct)

Holdings Before and After: Common Stock, 20,000 to 31,312 shares (Direct)

Other Insiders: 7 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cabaletta Bio (CABA) report for Gwendolyn Binder?

The filing reports that Gwendolyn Binder, President, Science & Tech. of Cabaletta Bio, purchased 11,312 shares of the company’s common stock in an open-market transaction.

When did Gwendolyn Binder buy Cabaletta Bio (CABA) shares and at what price?

On January 21, 2026, Gwendolyn Binder bought 11,312 Cabaletta Bio common shares at a price of $2.1891 per share.

How many Cabaletta Bio shares does Gwendolyn Binder own after this Form 4 transaction?

After the reported purchase, Gwendolyn Binder beneficially owns 31,312 shares of Cabaletta Bio common stock, held in direct ownership.

What is Gwendolyn Binder’s role at Cabaletta Bio (CABA)?

Gwendolyn Binder is an officer of Cabaletta Bio, serving as President, Science & Tech., according to the Form 4 filing.

Is the Cabaletta Bio (CABA) Form 4 transaction a purchase or a sale?

The Form 4 discloses a purchase transaction, coded “P”, for 11,312 shares of Cabaletta Bio common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Binder Gwendolyn

(Last) (First) (Middle)

C/O CABALETTA BIO, INC.

2929 ARCH STREET, SUITE 600

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cabaletta Bio, Inc. [ CABA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Science & Tech.

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		P		11,312	A	$2.1891	31,312	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	By: /s/ Michael Gerard, as Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.